CELEX: 62017TN0354
Language: en
Date: 2017-06-06 00:00:00
Title: Case T-354/17: Action brought on 6 June 2017 — Genomic Health v EUIPO (ONCOTYPE DX GENOMIC PROSTATE SCORE)

31.7.2017   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 249/41
            
         Action brought on 6 June 2017 — Genomic Health v EUIPO (ONCOTYPE DX GENOMIC PROSTATE SCORE)
   (Case T-354/17)
   (2017/C 249/55)
   Language of the case: English
   
      Parties
   
   
      Applicant: Genomic Health, Inc. (Redwood City, California, United States) (represented by: A. Reid, Solicitor)
   
      Defendant: European Union Intellectual Property Office (EUIPO)
   
      Details of the proceedings before EUIPO
   
   
      Trade mark at issue: EU word mark ‘ONCOTYPE DX GENOMIC PROSTATE SCORE’ — Application for registration No 15 214 257
   
      Contested decision: Decision of the Fifth Board of Appeal of EUIPO of 14 February 2017 in Case R 1682/2016-5
   
      Form of order sought
   
   The applicant claims that the Court should:
   
               —
            
            
               annul the contested decision;
            
         
               —
            
            
               order EUIPO to pay the Applicant’s costs of and occasioned by this appeal.
            
         
      Pleas in law
   
   The Applicant submits that the Contested Decision is incorrect and constitutes an:
   
               —
            
            
               Infringement of the general principles of equal treatment, good administration and legal certainty;
            
         
               —
            
            
               Infringement of Article 7(1)(b) in conjunction with Article 7(2) of Regulation No 207/2009;
            
         
               —
            
            
               Infringement of Article 7(1)(c) in conjunction with Article 7(2) of Regulation No. 207/2009.